Pharmacokinetic assessment of a fast-release orodispersible tramadol tablet compared to a conventional tramadol capsule

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 5, 2004, Pages 293-297

  Tagarro, Ignacio ^a   Vauzelle Kervroedan, Francoise ^b   Díez, Mary Carmen ^a  

^a Viatris Inc   (Spain)

^b Ethypharm   (France)

Author keywords

CAS 27203 92 5; Tramadol, orodispersible, pharmacokinetics; Zamadol Melt, bioavailability, bioequivalence, drug delivery

Indexed keywords

DRUG METABOLITE; O NORTRAMADOL; TRAMADOL; UNCLASSIFIED DRUG; ZAMADOL;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CAPSULE; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; GASTROINTESTINAL TRACT; HEALTH STATUS; HUMAN; MALE; MOLECULE; MOUTH; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SALIVA; STATISTICAL ANALYSIS; SWALLOWING; TABLET; VOLUNTEER;

EID: 2542579404     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296973     Document Type: Article

References (12)

1. Bamigbade, T. A., Langford, R. M., The clinical use of tramadol hydrochloride. Pain Rev. 5, 155 (1998)
2. Hennies, H. H., Friderichs, E., Schneider, J., Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneim.-Forsch./Drug Res. 38, 877 (1988)
3. Raffa, R. B., Friderichs, E., Reimann, W. et al., Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J. Pharmacol. Exp. Ther. 260, 275 (1992)
4. Driessen, B., Reimann, W., Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br. J. Pharmacol. 105, 147 (1992)
5. Reig, E., Tramadol in musculoskeletal pain - a survey. Clin. Rheumatol. Suppl. 1, S9 (2002)
6. Budd, K., Chronic pain - challenge and response. Drugs. 47 (Suppl. 1), 33 (1994)
7. Cicero, T. J., Adams, E. H., Geller, A. et al., A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 57, 7 (1999)
8. Spiller, H. A., Gorman, S. E., Villalobos, D. et al., Prospective multicenter evaluation of tramadol exposure. J. Toxicol. Clin. Toxicol. 35, 361 (1997)
9. Shipton, E. A., Tramadol-present and future. Anaesth. Intensive Care 28, 363 (2000)
10. Ruoff, G. E., Slowing the initial titration rate of tramadol improves tolerability. Pharmacotherapy 19, 388 (1999)
11. EMEA, Committee for Propietary Medicinal Products, Note for guidance on the investigation of bioavailability and bioequivalence. London, 26 July 2001. CPMP/EWP/QWP/1401/98 (2001)
12. Lintz, W., Barth, H., Osterloh, G. et al., Bioavailability of enterai tramadol formulations. Arzneim.-Forsch./Drug Res. 36 (II), 1278 (1986)